448 related articles for article (PubMed ID: 15720356)
21. Clinical advantages of combined seton placement and infliximab maintenance therapy for perianal fistulizing Crohn's disease: when and how were the seton drains removed?
Tanaka S; Matsuo K; Sasaki T; Nakano M; Sakai K; Beppu R; Yamashita Y; Maeda K; Aoyagi K
Hepatogastroenterology; 2010; 57(97):3-7. PubMed ID: 20422862
[TBL] [Abstract][Full Text] [Related]
22. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease.
Baert F; Noman M; Vermeire S; Van Assche G; D' Haens G; Carbonez A; Rutgeerts P
N Engl J Med; 2003 Feb; 348(7):601-8. PubMed ID: 12584368
[TBL] [Abstract][Full Text] [Related]
23. [Infliximab therapy for Crohn's disease anoperineal lesions].
Ouraghi A; Nieuviarts S; Mougenel JL; Allez M; Barthet M; Carbonnel F; Cosnes J; Gendre JP; Flourié B; Meurisse JJ; Quandalle P; Ernst O; Lemann M; Cortot A; Modigliani R; Colombel JF
Gastroenterol Clin Biol; 2001 Nov; 25(11):949-56. PubMed ID: 11845044
[TBL] [Abstract][Full Text] [Related]
24. Accelerated infliximab infusions are safe and well tolerated in patients with inflammatory bowel disease.
Clare DF; Alexander FC; Mike S; Dan G; Allan F; Lisa W; Peter HJ
Eur J Gastroenterol Hepatol; 2009 Jan; 21(1):71-5. PubMed ID: 19060632
[TBL] [Abstract][Full Text] [Related]
25. Infliximab for the treatment of fistulas in patients with Crohn's disease.
Present DH; Rutgeerts P; Targan S; Hanauer SB; Mayer L; van Hogezand RA; Podolsky DK; Sands BE; Braakman T; DeWoody KL; Schaible TF; van Deventer SJ
N Engl J Med; 1999 May; 340(18):1398-405. PubMed ID: 10228190
[TBL] [Abstract][Full Text] [Related]
26. Maintenance infliximab does not result in increased abscess development in fistulizing Crohn's disease: results from the ACCENT II study.
Sands BE; Blank MA; Diamond RH; Barrett JP; Van Deventer SJ
Aliment Pharmacol Ther; 2006 Apr; 23(8):1127-36. PubMed ID: 16611273
[TBL] [Abstract][Full Text] [Related]
27. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial.
Farrell RJ; Alsahli M; Jeen YT; Falchuk KR; Peppercorn MA; Michetti P
Gastroenterology; 2003 Apr; 124(4):917-24. PubMed ID: 12671888
[TBL] [Abstract][Full Text] [Related]
28. Infliximab in the treatment of Crohn's disease: a user's guide for clinicians.
Sandborn WJ; Hanauer SB
Am J Gastroenterol; 2002 Dec; 97(12):2962-72. PubMed ID: 12492177
[TBL] [Abstract][Full Text] [Related]
29. Clinical experience with infliximab therapy in 100 patients with Crohn's disease.
Farrell RJ; Shah SA; Lodhavia PJ; Alsahli M; Falchuk KR; Michetti P; Peppercorn MA
Am J Gastroenterol; 2000 Dec; 95(12):3490-7. PubMed ID: 11151882
[TBL] [Abstract][Full Text] [Related]
30. Successful induction of tolerance to infliximab in patients with Crohn's disease and prior severe infusion reactions.
Duburque C; Lelong J; Iacob R; Seddik M; Desreumaux P; Fournier C; Wallaert B; Cortot A; Colombel JF
Aliment Pharmacol Ther; 2006 Sep; 24(5):851-8. PubMed ID: 16918890
[TBL] [Abstract][Full Text] [Related]
31. Management of Crohn's disease of the ileoanal pouch with infliximab.
Colombel JF; Ricart E; Loftus EV; Tremaine WJ; Young-Fadok T; Dozois EJ; Wolff BG; Devine R; Pemberton JH; Sandborn WJ
Am J Gastroenterol; 2003 Oct; 98(10):2239-44. PubMed ID: 14572574
[TBL] [Abstract][Full Text] [Related]
32. Guidelines for treatment with infliximab for Crohn's disease.
Hommes DW; Oldenburg B; van Bodegraven AA; van Hogezand RA; de Jong DJ; Romberg-Camps MJ; van der Woude J; Dijkstra G;
Neth J Med; 2006; 64(7):219-29. PubMed ID: 16929083
[TBL] [Abstract][Full Text] [Related]
33. Effect of concurrent elemental diet on infliximab treatment for Crohn's disease.
Tanaka T; Takahama K; Kimura T; Mizuno T; Nagasaka M; Iwata K; Nakano H; Muramatsu M; Takazoe M
J Gastroenterol Hepatol; 2006 Jul; 21(7):1143-9. PubMed ID: 16824066
[TBL] [Abstract][Full Text] [Related]
34. Management of refractory fistulizing pouchitis with infliximab.
Viscido A; Kohn A; Papi C; Caprilli R
Eur Rev Med Pharmacol Sci; 2004; 8(5):239-46. PubMed ID: 15638238
[TBL] [Abstract][Full Text] [Related]
35. [Infliximab therapy in children and adolescents with refractory Crohn's disease in the Netherlands; experience with 23 patients].
de Ridder L; Escher JC; Taminiau JA
Ned Tijdschr Geneeskd; 2002 Oct; 146(40):1879-83. PubMed ID: 12395595
[TBL] [Abstract][Full Text] [Related]
36. Magnetic resonance imaging of the effects of infliximab on perianal fistulizing Crohn's disease.
Van Assche G; Vanbeckevoort D; Bielen D; Coremans G; Aerden I; Noman M; D'Hoore A; Penninckx F; Marchal G; Cornillie F; Rutgeerts P
Am J Gastroenterol; 2003 Feb; 98(2):332-9. PubMed ID: 12591051
[TBL] [Abstract][Full Text] [Related]
37. Results of seton drainage and infliximab infusion for complex anal Crohn's disease.
Hotokezaka M; Ikeda T; Uchiyama S; Tsuchiya K; Chijiiwa K
Hepatogastroenterology; 2011; 58(109):1189-92. PubMed ID: 21937376
[TBL] [Abstract][Full Text] [Related]
38. Use of infliximab in the treatment of Crohn's disease in children and adolescents.
Hyams JS; Markowitz J; Wyllie R
J Pediatr; 2000 Aug; 137(2):192-6. PubMed ID: 10931411
[TBL] [Abstract][Full Text] [Related]
39. Autoantibody profile during short-term infliximab treatment for Crohn's disease: a prospective cohort study.
Atzeni F; Ardizzone S; Sarzi-Puttini P; Colombo E; Maconi G; De Portu S; Carrabba M; Bianchi Porro G
Aliment Pharmacol Ther; 2005 Sep; 22(5):453-61. PubMed ID: 16128684
[TBL] [Abstract][Full Text] [Related]
40. [Treatment of Crohn's disease with anti-TNF alpha antibodies (infliximab): results of a multicentric and retrospective study].
Doubremelle M; Bourreille A; Zerbib F; Heresbach D; Metman EH; Beau P; Gournay J; Galmiche JP
Gastroenterol Clin Biol; 2002 Nov; 26(11):973-9. PubMed ID: 12483127
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
